Denatured G-Protein Coupled Receptors as Immunogens to Generate Highly Specific Antibodies

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Talmont, Franck ^a,b   Moulédous, Lionel ^a,b   Boué, Jérôme ^b,c,d   Mollereau, Catherine ^a,b   Dietrich, Gilles ^b,c,d  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c INSERM   (France)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR ANTIGEN; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NEUROPEPTIDE FF2 RECEPTOR; RECOMBINANT G PROTEIN COUPLED RECEPTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DENATURATION; PROTEIN PURIFICATION; PROTEIN UNFOLDING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PICHIA; PROTEIN DENATURATION; PROTEIN FOLDING; RECEPTORS, NEUROPEPTIDE; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 84866897272     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046348     Document Type: Article

References (44)

1. Bjarnadottir TK, Gloriam DE, Hellstrand SH, Kristiansson H, Fredriksson R, et al. (2006) Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics 88: 263-273.
2. Schioth HB, Fredriksson R, (2005) The GRAFS classification system of G-protein coupled receptors in comparative perspective. Gen Comp Endocrinol 142: 94-101.
3. Gupta A, Devi LA, (2006) The use of receptor-specific antibodies to study G-protein-coupled receptors. Mt Sinai J Med 73: 673-681.
4. Sarramegna V, Muller I, Milon A, Talmont F, (2006) Recombinant G protein-coupled receptors from expression to renaturation: a challenge towards structure. Cell Mol Life Sci 63: 1149-1164.
5. Harrison C, van der Graaf PH, (2006) Current methods used to investigate G protein coupled receptor oligomerisation. J Pharmacol Toxicol Methods 54: 26-35.
6. Bockaert J, Dumuis A, Fagni L, Marin P, (2004) GPCR-GIP networks: a first step in the discovery of new therapeutic drugs? Curr Opin Drug Discov Devel 7: 649-657.
7. Day PW, Rasmussen SG, Parnot C, Fung JJ, Masood A, et al. (2007) A monoclonal antibody for G protein-coupled receptor crystallography. Nat Methods 4: 927-929.
8. Hino T, Arakawa T, Iwanari H, Yurugi-Kobayashi T, Ikeda-Suno C, et al. (2012) G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. Nature 482: 237-240.
9. Gupta A, Decaillot FM, Gomes I, Tkalych O, Heimann AS, et al. (2007) Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem 282: 5116-5124.
10. Hutchings CJ, Koglin M, Marshall FH, (2010) Therapeutic antibodies directed at G protein-coupled receptors. MAbs 2: 594-606.
11. Boue J, Blanpied C, Brousset P, Vergnolle N, Dietrich G, (2011) Endogenous opioid-mediated analgesia is dependent on adaptive T cell response in mice. J Immunol 186: 5078-5084.
12. Boue J, Blanpied C, Djata-Cabral M, Pelletier L, Vergnolle N, et al. (2012) Immune conditions associated with CD4(+) T effector-induced opioid release and analgesia. Pain 153: 485-493.
13. Mace G, Blanpied C, Emorine LJ, Druet P, Dietrich G, (1999) Isolation and characterization of natural human IgG with a morphine-like activity. Eur J Immunol 29: 997-1003.
14. Stein C, Machelska H, (2011) Modulation of peripheral sensory neurons by the immune system: implications for pain therapy. Pharmacol Rev 63: 860-881.
15. Huang L, Sato AK, Sachdeva M, Fleming T, Townsend S, et al. (2005) Discovery of human antibodies against the C5aR target using phage display technology. J Mol Recognit 18: 327-333.
16. Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, et al. (2009) Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 137: 1148-1159.
17. Beermann S, Seifert R, Neumann D, (2011) Commercially available antibodies against human and murine histamine H(4)-receptor lack specificity. Naunyn Schmiedebergs Arch Pharmacol 385: 125-135.
18. Hamdani N, van der Velden J, (2009) Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379: 403-407.
19. Jensen BC, Swigart PM, Simpson PC, (2009) Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch Pharmacol 379: 409-412.
20. Jositsch G, Papadakis T, Haberberger RV, Wolff M, Wess J, et al. (2009) Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 379: 389-395.
21. Lu X, Bartfai T, (2009) Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice. Naunyn Schmiedebergs Arch Pharmacol 379: 417-420.
22. Pradidarcheep W, Stallen J, Labruyere WT, Dabhoiwala NF, Michel MC, et al. (2009) Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379: 397-402.
23. Niwa H, Rowbotham DJ, Lambert DG, (2012) Evaluation of primary opioid receptor antibodies for use in western blotting. Br J Anaesth 108: 530-532.
24. Mace G, Jaume M, Blanpied C, Stephan L, Coudert JD, et al. (2002) Anti-mu-opioid-receptor IgG antibodies are commonly present in serum from healthy blood donors: evidence for a role in apoptotic immune cell death. Blood 100: 3261-3268.
25. Mancia F, Brenner-Morton S, Siegel R, Assur Z, Sun Y, et al. (2007) Production and characterization of monoclonal antibodies sensitive to conformation in the 5HT2c serotonin receptor. Proc Natl Acad Sci U S A 104: 4303-4308.
26. Baneres JL, Popot JL, Mouillac B, (2011) New advances in production and functional folding of G-protein-coupled receptors. Trends Biotechnol 29: 314-322.
27. Koutsopoulos S, Kaiser L, Eriksson HM, Zhang S, (2011) Designer peptide surfactants stabilize diverse functional membrane proteins. Chem Soc Rev.
28. Sarramegna V, Talmont F, Demange P, Milon A, (2003) Heterologous expression of G-protein-coupled receptors: comparison of expression systems fron the standpoint of large-scale production and purification. Cell Mol Life Sci 60: 1529-1546.
29. Asada H, Uemura T, Yurugi-Kobayashi T, Shiroishi M, Shimamura T, et al. (2011) Evaluation of the Pichia pastoris expression system for the production of GPCRs for structural analysis. Microb Cell Fact 10: 24.
30. Sarramegna V, Muller I, Mousseau G, Froment C, Monsarrat B, et al. (2005) Solubilization, purification, and mass spectrometry analysis of the human mu-opioid receptor expressed in Pichia pastoris. Protein Expr Purif 43: 85-93.
31. Singh S, Gras A, Fiez-Vandal C, Ruprecht J, Rana R, et al. (2008) Large-scale functional expression of WT and truncated human adenosine A2A receptor in Pichia pastoris bioreactor cultures. Microb Cell Fact 7: 28.
32. Mouledous L, Neasta J, Uttenweiler-Joseph S, Stella A, Matondo M, et al. (2005) Long-term morphine treatment enhances proteasome-dependent degradation of G beta in human neuroblastoma SH-SY5Y cells: correlation with onset of adenylate cyclase sensitization. Mol Pharmacol 68: 467-476.
33. Tansky MF, Pothoulakis C, Leeman SE, (2007) Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor. Proc Natl Acad Sci U S A 104: 10691-10696.
34. Combet C, Blanchet C, Geourjon C, Deleage G, (2000) NPS@: network protein sequence analysis. Trends Biochem Sci 25: 147-150.
35. Agirregoitia E, Valdivia A, Carracedo A, Casis L, Gil J, et al. (2006) Expression and localization of delta-, kappa-, and mu-opioid receptors in human spermatozoa and implications for sperm motility. J Clin Endocrinol Metab 91: 4969-4975.
36. Kazmi SM, Mishra RK, (1987) Comparative pharmacological properties and functional coupling of mu and delta opioid receptor sites in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 32: 109-118.
37. Peckys D, Landwehrmeyer GB, (1999) Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience 88: 1093-1135.
38. Kivell BM, Day DJ, McDonald FJ, Miller JH, (2004) Mu and delta opioid receptor immunoreactivity and mu receptor regulation in brainstem cells cultured from late fetal and early postnatal rats. Brain Res Dev Brain Res 149: 9-19.
39. Muller I, Sarramegna V, Milon A, Talmont FJ, (2010) The N-terminal end truncated mu-opioid receptor: from expression to circular dichroism analysis. Appl Biochem Biotechnol 160: 2175-2186.
40. Muller I, Sarramegna V, Renault M, Lafaquiere V, Sebai S, et al. (2008) The full-length mu-opioid receptor: a conformational study by circular dichroism in trifluoroethanol and membrane-mimetic environments. J Membr Biol 223: 49-57.
41. Mace G, Blanpied C, Emorine LJ, Druet P, Dietrich G, (1999) Morphine-like activity of natural human IgG autoantibodies is because of binding to the first and third extracellular loops of the mu-opioid receptor. J Biol Chem 274: 20079-20082.
42. Dietrich G, Gaibelet G, Capeyrou R, Butour JL, Pontet F, et al. (1998) Implication of the first and third extracellular loops of the mu-opioid receptor in the formation of the ligand binding site: a study using chimeric mu-opioid/angiotensin receptors. J Neurochem 70: 2106-2111.
43. Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, et al. (1994) ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 341: 33-38.
44. Mollereau C, Mazarguil H, Zajac JM, Roumy M, (2005) Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells. Mol Pharmacol 67: 965-975.